このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

LumiraDx マネジメント

マネジメント基準チェック /24

LumiraDx'sの CEO はVeronique Ameyeで、 Feb2015年に任命され、の在任期間は 9.33年です。は、会社の株式の0.038%を直接所有しており、その価値は$ 2.32K 。経営陣と取締役会の平均在任期間はそれぞれ8.5年と6.4年です。

主要情報

Veronique Ameye

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	9.4yrs
CEOの所有権	0.04%
経営陣の平均在職期間	8.5yrs
取締役会の平均在任期間	6.5yrs

経営陣の近況

Recent updates

Market Cool On LumiraDx Limited's (NASDAQ:LMDX) Revenues Pushing Shares 27% Lower

Dec 20

LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors

Apr 17

What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today

Nov 16

Need To Know: The Consensus Just Cut Its LumiraDx Limited (NASDAQ:LMDX) Estimates For 2022

Aug 20

LumiraDx GAAP EPS of -$0.58, revenue of $44.7M

Aug 18

Bill & Melinda Gates Foundation discloses 7.4% passive stake in LumiraDx

Jul 15

CEO（最高経営責任者

Veronique Ameye (48 yo)

9.4yrs

在職期間

Ms. Veronique Ameye, Esq. EMBA, has been General Counsel at LumiraDx Limited since February 2015, serves as its Chief Executive Officer since November 01, 2023, served as its Deputy Chief Executive Officer...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Veronique Ameye	CEO & General Counsel	9.4yrs	データなし	0.038% $ 1.6k
Dorian LeBlanc	CFO & VP of Global Operations	7.7yrs	データなし	0.073% $ 3.1k
Colleen McMillen	Vice President of Communications	no data	データなし	データなし
Andy Ward	National Sales Director - UK	no data	データなし	データなし
David Walton	Chief Commercial Officer	9.9yrs	データなし	0.25% $ 10.9k
Giffin Daughtridge	President of North America Commercial Operations & Global Molecular Solutions	less than a year	データなし	データなし
Melissa Garcia	VP & Corporate Counsel	no data	データなし	データなし

8.5yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: LMDX.Fの経営陣は経験豊富で経験豊富です（平均在職期間は8.5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Troyen Brennan	Non-Employee Director	7.7yrs	データなし	0% $ 0
Bruce Keogh	Independent Non-Employee Director	6.5yrs	データなし	0% $ 0
George Neble	Independent Co-Chairman of the Board	4yrs	データなし	0.0098% $ 422.5
Donald Berwick	Independent Non-Employee Director	6.5yrs	データなし	0% $ 0
Lurene Julia Joseph	Independent Co-Chairman of the Board	7.7yrs	データなし	0% $ 0

6.5yrs

平均在職期間

69yo

平均年齢

経験豊富なボード: LMDX.Fの取締役会は経験豊富であると考えられます ( 6.4年の平均在任期間)。

LumiraDx マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

LumiraDx Limited Announces Resignation of Ron Zwanziger as Chief Executive Officer

LumiraDx Limited Announces Resignation of Gerald L. Chan from the Board of Directors

LumiraDx Limited Announces Executive Changes

Insufficient new directors

LumiraDx Limited, Annual General Meeting, Dec 15, 2022

Recent updates

Nasdaq to Delist Common Stock of LumiraDx Limited

LumiraDx Limited(OTCPK:LMDX.F) dropped from NASDAQ Composite Index

LumiraDx Announces Its Securities To Be Suspended from Trading on Nasdaq At the Open of Business on January 9, 2024

Nasdaq to Suspend Trading of LumiraDx's Securities and to File Form 25-NSE with SEC

Market Cool On LumiraDx Limited's (NASDAQ:LMDX) Revenues Pushing Shares 27% Lower

LumiraDx Limited Announces Resignation of Ron Zwanziger as Chief Executive Officer

LumiraDx Announces Receipt of Nasdaq Delisting Determination, Plans to Appeal

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

LumiraDx Limited Announces Resignation of Gerald L. Chan from the Board of Directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

LumiraDx Limited Announces Executive Changes

LumiraDx Limited to Report Q2, 2023 Results on Aug 24, 2023

Insufficient new directors

LumiraDx Limited to Report Q1, 2023 Results on May 16, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors

Price target decreased by 12% to US$1.83

Consensus revenue estimates decrease by 51%, EPS upgraded

Price target decreased by 29% to US$2.49

Full year 2022 earnings: EPS and revenues miss analyst expectations

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

Lumiradx Receives FDA Emergency Use Authorization and UK CTDA Approval for Its Fast Lab Solutions Multiplex Covid and Influenza Molecular Assay

LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

LumiraDx Limited Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today

LumiraDx Limited, Annual General Meeting, Dec 15, 2022

Price target decreased to US$4.31

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Third quarter 2022 earnings: Revenues exceed analyst expectations

LumiraDx Limited to Report Q3, 2022 Results on Nov 09, 2022

LumiraDx Partners with British in Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance

Consensus EPS estimates fall by 25%

Need To Know: The Consensus Just Cut Its LumiraDx Limited (NASDAQ:LMDX) Estimates For 2022

Price target decreased to US$6.38

Second quarter 2022 earnings: Revenues miss analyst expectations

LumiraDx GAAP EPS of -$0.58, revenue of $44.7M

LumiraDx Limited to Report Q2, 2022 Results on Aug 18, 2022

Investor sentiment deteriorated over the past week

LumiraDx Limited has completed a Follow-on Equity Offering in the amount of $75.25 million.

Bill & Melinda Gates Foundation discloses 7.4% passive stake in LumiraDx

Investor sentiment deteriorated over the past week

Price target decreased to US$7.63

Price target decreased to US$8.00

Investor sentiment deteriorated over the past week

LumiraDx Limited Expands Its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

LumiraDx Limited Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking

Consensus EPS estimates fall by 72%

Price target decreased to US$9.75

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

LumiraDx Limited to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$10.56

Consensus EPS estimates fall by 75%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

LumiraDx Limited to Report Q4, 2021 Results on Mar 10, 2022

LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete

Consensus EPS estimates increase by 96%

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

LumiraDx Limited Provides Revenue Guidance for the Fourth Quarter and Full Year of 2021

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions

Third quarter 2021 earnings released: EPS US$0.63 (vs US$0.82 loss in 3Q 2020)

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

マネジメント基準チェック /24